MDx Coding Changes Impact Sequenom's Dx Revenues; Company May 'Curtail' Some Services | GenomeWeb

This story was originally published July 25.

Despite a 91 percent increase in revenues in the second quarter, Sequenom said today that changes to how molecular diagnostic tests are coded and billed are impacting its ability to get reimbursed.

As such, President and CEO Harry Hixson said during a conference call to discuss the company's second quarter earnings that it plans to implement expense reduction initiatives that could include the "curtailment of services for which there is no current reimbursement available."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."